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Plenary Presentation 1 – Hepatitis C
PL-001 ISG15, an ubiquitin-like interferon stimulated
gene, promotes HCV production in vitro
Limin Chen*, Jing Sun, Larry Meng, Jenny Heathcote,
Aled Edwards, Ian McGilvray. University of Toronto, Toronto,
Canada
Objectives: Chronic hepatitis C virus (CHC) infection is treated
with interferon/ribavirin, but only a subset of patients re-
spond. The molecular mechanism of interferon resistance is not
well undertstood. We previously reported that treatment non-
responders have marked pre-treatment upregulation of a subset
of interferon stimulated genes (ISGs) in their livers, includ-
ing ISG15 (Chen, et al. Gastroenterology 2005) and discovered
ISG15/USP18 pathway is involved in interferon resistance (Ran-
dall, et al. Gastroenterology 2006). Here, we study the effect of
ISG15 on HCV production in J6/JFH1 culture system.
Methods: ISG15 expression and its conjugation (ISGylation) was
manipulated in two ways: up-regulated by plasmid transfec-
tion and inhibited by silencing the E1 activating enzyme Ube1L
using speciﬁc SiRNA. The effect of increased or decreased
ISG15/ISGylation on HCV RNA replication and viral particle pro-
duction was monitored by real-time PCR and NS5A staining,
respectively.
Results: Overexpression of ISG15 increased ISGylation in Huh7.5
cells and promoted HCV RNA replication and virion secretion. Si-
lencing Ube1L ablated ISGylation and inhibited HCV production.
This pro-HCV effect of ISG15 is not mediated through extracel-
lular free form ISG15 nor from perturbing the Jak/STAT signaling
pathway.
Conclusions: Contrary to many published studies on the anti-
viral activity of ISG15 in a number of viral models, ISG15 is a
pro-HCV molecule in vitro. This ﬁnding may help to explain why
increased ISG15 in the pretreatment liver tissue is correlated
with treatment failure, and suggests that manipulating ISG15
may be a potential approach for HCV therapy.
Plenary Presentation 2 – Bacterial Infections/
Antibiotics I
PL-002 Pharmacokinetic-pharmacodynamic proﬁling of
four antimicrobials against Gram-negative
bacteria collected from Shenyang, China
Yun Zhuo Chu1, Su Fei Tian*,1, Hua Nian1, Hong Shang1, Hong
Sheng Pan1, Bai Yi Chen2. 1Department of Laboratory Medicine,
2Division of Infectious Diseases, The First Afﬁliated Hospital of
China Medical University
Objectives: To examine common antimicrobial regimens used in
eradicationg certain nosocomial Gram-negative pathogens and
determine which ones are likely to be the most suitable as
empirical choices in Shenyang, China.
Methods: A 5000-subject Monte Carlo simulation was conducted
to determine the cumulative fraction of response (CFR) for
meropenem, imipenem, cefepime, piperacillin/tazobactam and
levoﬂoxacin against Escherichia coli, Klebsiella pneumoniae, En-
terobacter cloacae, Acinetobacter baumannii and Pseudomonas
aeruginosa collected in 2006 and 2007 from Shenyang.
Results: Meropenem and imipenem had the highest CFRs against
the Enterobacteriaceae (97–100%), followed by cefepime. No
antibiotic simulated regimen achieved optimal CFR against P.
aeruginosa and A. baumannii. Piperacillin/tazobactam dosed at
4.5g q8h achieved the lowest CFR against all bacteria.
Bactericidal CFR (%)
E. K. E. P. A.
coli pneumoniae cloacae aeruginosa baumannii
Meropenem 0.5g q6h 100 100 100 52 59
Meropenem 0.5g q8h 100 100 97 46 59
Meropenem 1g q8h 100 100 100 54 59
Imipenem 0.5g q6h 100 99 97 45 36
Imipenem 0.5g q8h 100 97 97 36 34
Imipenem 1g q8h 100 99 98 49 37
Cefepime 1g q8h 90 73 68 48 22
Cefepime 2g q8h 95 83 78 68 37
Cefepime 1g q12h 90 74 68 45 22
Piperacillin/tazobactam
4.5g q8h 71 33 34 11 8
Levoﬂoxacin 0.5g
every 24h 30 44 68 33 19
Conclusions: This study suggests that the carbapenems provide
the greatest likelihood of clinical success for the Enterobacteri-
aceae, and combination therapy might be needed when choosing
empirical therapy, especially when A. baumannii or P. aeruginosa
are suspected.
Plenary Presentation 3 – Parasitic/Gastro-intestinal
Infections
PL-003 Protective effect of a pvax1-Ts87 DNA vaccine
delivered in attenuated Salmonella typhimurium
against Trichinella spiralis infection in mice
Yaping Yang*,1, Xiaoqin Chen1, Zhifei Zhang1, Jing Yang1,
Jinsheng He2, Xinping Zhu1. 1Department of Parasitology,
School of Basic Medical Sciences, Capital Medical University,
Beijing, PR China; 2Institute of Bioscience and Biotechnology,
School of Science, Beijing Jiaotong University, Beijing, PR China
Objectives: Trichinellosis is a widespread zoonosis mainly caused
by Trichinella spiralis. Mucosal immunization is very important
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